A novel approach to overcome multidrug resistance: Utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors

Yuta Yoshizawa, Ken Ichi Ogawara, Toshikiro Kimura, Kazutaka Higaki

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX). First of all, established were PTX-resistant Colon-26 cancer cells (C26/PTX) overexpressing P-gp, which provided IC50 value of PTX solution about 30 times larger than that obtained for control C26 (C26/control) in the in vitro MTT assay. Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX. However, the in vivo anti-tumor effect of PL-PTX in C26/PTX-bearing mice was similar to that in C26/control-bearing mice. Double immunohistochemical staining of vascular endothelial cells and apoptotic cells within tumor tissues demonstrated that the apoptotic cell death was preferentially observed in vascular endothelial cells in C26/PTX tumors after intravenous administration of PL-PTX, while that was in tumor cells in C26/control tumors. These results suggest that the in vivo anti-tumor effect of PL-PTX in C26/PTX-bearing mice would be ascribed to the cytotoxic action of PTX pumped out of tumor cells by overexpressed P-gp to vascular endothelial cells in tumor tissues.

Original languageEnglish
Pages (from-to)274-280
Number of pages7
JournalEuropean Journal of Pharmaceutical Sciences
Volume62
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Multiple Drug Resistance
P-Glycoprotein
Paclitaxel
Endothelial Cells
Neoplasms
Intravenous Administration
Colonic Neoplasms

Keywords

  • Apoptosis
  • Liposome
  • P-glycoprotein
  • Paclitaxel
  • Vascular endothelial cells

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Medicine(all)

Cite this

A novel approach to overcome multidrug resistance : Utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors. / Yoshizawa, Yuta; Ogawara, Ken Ichi; Kimura, Toshikiro; Higaki, Kazutaka.

In: European Journal of Pharmaceutical Sciences, Vol. 62, 01.10.2014, p. 274-280.

Research output: Contribution to journalArticle

@article{51551140264040629c15a30ecf26a0de,
title = "A novel approach to overcome multidrug resistance: Utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors",
abstract = "We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX). First of all, established were PTX-resistant Colon-26 cancer cells (C26/PTX) overexpressing P-gp, which provided IC50 value of PTX solution about 30 times larger than that obtained for control C26 (C26/control) in the in vitro MTT assay. Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX. However, the in vivo anti-tumor effect of PL-PTX in C26/PTX-bearing mice was similar to that in C26/control-bearing mice. Double immunohistochemical staining of vascular endothelial cells and apoptotic cells within tumor tissues demonstrated that the apoptotic cell death was preferentially observed in vascular endothelial cells in C26/PTX tumors after intravenous administration of PL-PTX, while that was in tumor cells in C26/control tumors. These results suggest that the in vivo anti-tumor effect of PL-PTX in C26/PTX-bearing mice would be ascribed to the cytotoxic action of PTX pumped out of tumor cells by overexpressed P-gp to vascular endothelial cells in tumor tissues.",
keywords = "Apoptosis, Liposome, P-glycoprotein, Paclitaxel, Vascular endothelial cells",
author = "Yuta Yoshizawa and Ogawara, {Ken Ichi} and Toshikiro Kimura and Kazutaka Higaki",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.ejps.2014.06.009",
language = "English",
volume = "62",
pages = "274--280",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - A novel approach to overcome multidrug resistance

T2 - Utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors

AU - Yoshizawa, Yuta

AU - Ogawara, Ken Ichi

AU - Kimura, Toshikiro

AU - Higaki, Kazutaka

PY - 2014/10/1

Y1 - 2014/10/1

N2 - We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX). First of all, established were PTX-resistant Colon-26 cancer cells (C26/PTX) overexpressing P-gp, which provided IC50 value of PTX solution about 30 times larger than that obtained for control C26 (C26/control) in the in vitro MTT assay. Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX. However, the in vivo anti-tumor effect of PL-PTX in C26/PTX-bearing mice was similar to that in C26/control-bearing mice. Double immunohistochemical staining of vascular endothelial cells and apoptotic cells within tumor tissues demonstrated that the apoptotic cell death was preferentially observed in vascular endothelial cells in C26/PTX tumors after intravenous administration of PL-PTX, while that was in tumor cells in C26/control tumors. These results suggest that the in vivo anti-tumor effect of PL-PTX in C26/PTX-bearing mice would be ascribed to the cytotoxic action of PTX pumped out of tumor cells by overexpressed P-gp to vascular endothelial cells in tumor tissues.

AB - We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX). First of all, established were PTX-resistant Colon-26 cancer cells (C26/PTX) overexpressing P-gp, which provided IC50 value of PTX solution about 30 times larger than that obtained for control C26 (C26/control) in the in vitro MTT assay. Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX. However, the in vivo anti-tumor effect of PL-PTX in C26/PTX-bearing mice was similar to that in C26/control-bearing mice. Double immunohistochemical staining of vascular endothelial cells and apoptotic cells within tumor tissues demonstrated that the apoptotic cell death was preferentially observed in vascular endothelial cells in C26/PTX tumors after intravenous administration of PL-PTX, while that was in tumor cells in C26/control tumors. These results suggest that the in vivo anti-tumor effect of PL-PTX in C26/PTX-bearing mice would be ascribed to the cytotoxic action of PTX pumped out of tumor cells by overexpressed P-gp to vascular endothelial cells in tumor tissues.

KW - Apoptosis

KW - Liposome

KW - P-glycoprotein

KW - Paclitaxel

KW - Vascular endothelial cells

UR - http://www.scopus.com/inward/record.url?scp=84904024997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904024997&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2014.06.009

DO - 10.1016/j.ejps.2014.06.009

M3 - Article

C2 - 24956463

AN - SCOPUS:84904024997

VL - 62

SP - 274

EP - 280

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -